Serum soluble triggering receptor on myeloid cells-1 (sTREM-1) is elevated in systemic lupus erythematosus but does not distinguish between lupus alone and concurrent infection

Inflammation

Volumn 36, Issue 6, 2013, Pages 1519-1524

  Molad, Yair ^a,b   Pokroy Shapira, Elisheva ^b   Kaptzan, Tania ^a   Monselise, Assaf ^a   Shalita Chesner, Michal ^a   Monselise, Yehudit ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

Author keywords

infection; soluble triggering receptor expressed on myeloid cells 1 (sTREM 1); systemic lupus erythematosus; innate immunity; toll like receptor 9

Indexed keywords

CHLOROQUINE; GELATINASE B; OLIGONUCLEOTIDE; TOLL LIKE RECEPTOR; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1;

ADULT; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; BONE MARROW CELL; COHORT ANALYSIS; CONCURRENT INFECTION; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INNATE IMMUNITY; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ADULT; COHORT STUDIES; COINFECTION; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MACROPHAGES; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; RECEPTORS, IMMUNOLOGIC; TOLL-LIKE RECEPTOR 9;

EID: 84888202389     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-013-9694-z     Document Type: Article

References (35)

1. Waldner, H. 2009. The role of innate immune responses in autoimmune disease development. Autoimmunity Reviews 8: 400-404.
2. Tsokos, G.C. 2011. Systemic lupus erythematosus. The New England Journal of Medicine 365: 2110-2121.
3. Akira, S., S. Uematsu, and O. Takeuchi. 2006. Pathogen recognition and innate immunity. Cell 124(4): 783-801.
4. Rhee, J.W., K.W. Lee, W.J. Sohn, Y. Lee, O.H. Jeon, H.J. Kwon, and D.S. Kim. 2007. Regulation of matrix metalloproteinase-9 gene expression and cell migration by NF-kappa B in response to CpG-oligodeoxynucleotides in RAW 264.7 cells. Molecular Immunology 44(6): 1393-1400.
5. Christensen, S.R., M. Kashgarian, L. Alexopoulou, R.A. Flavell, S. Akira, and M.J. Shlomchik. 2005. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. The Journal of Experimental Medicine 202: 321-331.
6. Christensen, S.R., J. Shupe, K. Nickerson, M. Kashgarian, R.A. Flavell, and M.J. Shlomchik. 2006. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25: 417-428.
7. Sato, Y., M. Miyata, T. Nishimaki, H. Kochi, and R. Kasukawa. 1999. CpG motif-containing DNA fragments from sera of patients with systemic lupus erythematosus proliferate mononuclear cells in vitro. Journal of Rheumatology 26: 294-301.
8. Richez, C., P. Blanco, I. Rifkin, J.F. Moreau, and T. Schaeverbeke. 2011. Role for toll-like receptors in autoimmune disease: the example of systemic lupus erythematosus. Joint, Bone, Spine 78: 124-130.
9. Barrat, F.J., T. Meeker, J.H. Chan, C. Guiducci, and R.L. Coffman. 2007. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. European Journal of Immunology 37: 3582-3586.
10. Tao, K., M. Fujii, S. Tsukumo, Y. Maekawa, K. Kishihara, Y. Kimoto, et al. 2007. Genetic variations of toll-like receptor 9 predispose to systemic lupus erythematosus in Japanese population. Annals of the Rheumatic Diseases 66: 905-909.
11. Wu, O., G.P. Chen, H. Chen, X.P. Li, J.H. Xu, S.S. Zhao, et al. 2009. The expressions of toll-like receptor 9 and T-bet in circulating B and T cells in newly diagnosed, untreated systemic lupus erythematosus and correlations with disease activity and laboratory data in a Chinese population. Immunobiology 214: 392-402.
12. Bouchon, A., J. Dietrich, and M. Colonna. 2000. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. Journal of Immunology 164: 4991-4995.
13. Klesney-Tait, J., I.R. Turnbull, and M. Colonna. 2006. The TREM receptor family and signal integration. Nature Immunology 7: 1266-1273.
14. Sharif, O., and S. Knapp. 2008. From expression to signaling: roles of TREM-1 and TREM-2 in innate immunity and bacterial infection. Immunobiology 213(9-10): 701-713.
15. Bouchon, A., F. Facchetti, M.A. Weigand, and M. Colonna. 2001. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 410: 1103-1107.
16. Gibot, S., F. Massin, P. Le Renard, et al. 2005. Surface and soluble triggering receptor expressed on myeloid cells-1: expression patterns in murine sepsis. Critical Care Medicine 33: 1787-1793.
17. Gibot, S., C. Buonsanti, F. Massin, M. Romano, M.N. Kolopp-Sarda, F. Benigni, G.C. Faure, M.C. Béné, P. Panina-Bordignon, N. Passini, and B. Lévy. 2006. Modulation of the triggering receptor expressed on the myeloid cell type 1 pathway in murine septic shock. Infection and Immunity 74(5): 2823-2830.
18. Kuai, J., B. Gregory, A. Hill, D.D. Pittman, J.L. Feldman, T. Brown, B. Carito, M. O'Toole, R. Ramsey, O. Adolfsson, K.M. Shields, K. Dower, J.P. Hall, Y. Kurdi, J.T. Beech, J. Nanchahal, M. Feldmann, B.M. Foxwell, F.M. Brennan, D.G. Winkler, and L.L. Lin. 2009. TREM-1 expression is increased in the synovium of rheumatoid arthritis patients and induces the expression of pro-inflammatory cytokines. Rheumatology (Oxford, England) 48(11): 1352-1358.
19. Murakami, Y., T. Akahoshi, N. Aoki, M. Toyomoto, N. Miyasaka, and H. Kohsaka. 2009. Intervention of an inflammation amplifier, triggering receptor expressed on myeloid cells 1, for treatment of autoimmune arthritis. Arthritis and Rheumatism 60(6): 1615-1623.
20. Molad Y, Pokroy-Shapira E, Carmon V. CpG-oligodeoxynucleotide-induced TLR9 activation regulates macrophage TREM-1 expression and shedding. Innate Immun. 2013. doi: 10.1177/1753425913476970.
21. Tan, E.M., A.S. Cohen, J.F. Fries, et al. 1982. The 1982 revised criteria for classification of systemic lupus erythematosus. Arthritis and Rheumatism 25: 1271-1277.
22. Bombardier, C., D. Gladman, M.B. Urowitz, D. Caron, C.H. Chang, and the Committee on Prognosis Studies in SLE. 1992. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis and Rheumatism 35: 630-640.
23. Gibot, S., M.N. Kolopp-Sarda, M.C. Bene, A. Cravoisy, B. Levy, G.C. Faure, and P.E. Bollaert. 2004. Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis. Annals of Internal Medicine 141(1): 9-15.
24. Gibot, S., A. Cravoisy, B. Levy, M.C. Bene, G. Faure, and P.E. Bollaert. 2004. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. The New England Journal of Medicine 350(5): 451-458.
25. Determann, R.M., M. Weisfelt, J. de Gans, A. van der Ende, M.J. Schultz, and D. van de Beek. 2006. Soluble triggering receptor expressed on myeloid cells 1: a biomarker for bacterial meningitis. Intensive Care Medicine 32(8): 1243-1247.
26. Bishara, J., N. Hadari, M. Shalita-Chesner, Z. Samra, O. Ofir, M. Paul, N. Peled, S. Pitlik, and Y. Molad. 2007. Soluble triggering receptor expressed on myeloid cells-1 for distinguishing bacterial from aseptic meningitis in adults. European Journal of Clinical Microbiology and Infectious Diseases 26(9): 647-650.
27. Determann, R.M., J.W. van Till, O. van Ruler, S.Q. van Veen, M.J. Schultz, and M.A. Boermeester. 2009. sTREM-1 is a potential useful biomarker for exclusion of ongoing infection in patients with secondary peritonitis. Cytokine 46(1): 36-42.
28. Gibot, S., A. Cravoisy, M.N. Kolopp-Sarda, M.C. Bene, G. Faure, P.E. Bollaert, and B. Levy. 2005. Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma concentrations during sepsis. Critical Care Medicine 33(4): 792-796.
29. Su, L.X., L. Feng, J. Zhang, Y.J. Xiao, Y.H. Jia, P. Yan, D. Feng, and L.X. Xie. 2011. Diagnostic value of urine sTREM-1 for sepsis and relevant acute kidney injuries: a prospective study. Critical Care 15(5): R250.
30. Zhang, J., D. She, D. Feng, Y. Jia, and L. Xie. 2011. Dynamic changes of serum soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) reflect sepsis severity and can predict prognosis: a prospective study. BMC Infectious Diseases 11: 53.
31. Collins, C.E., D.T. La, H.T. Yang, F. Massin, S. Gibot, G. Faure, and W. Stohl. 2009. Elevated synovial expression of triggering receptor expressed on myeloid cells 1in patients with septic arthritis or rheumatoid arthritis. Annals of the Rheumatic Diseases 68(11): 1768-1774.
32. Saurer, L., S. Rihs, M. Birrer, N. Saxer-Seculic, M. Radsak, C. Mueller, et al. 2012. Elevated levels of serum-soluble triggering receptor expressed on myeloid cells-1in patients with IBD do not correlate with intestinal TREM-1 mRNA expression and endoscopic disease activity. Journal of Crohn's & Colitis 6(9): 913-923.
33. Kim, J., J.K. Koh, E.Y. Lee, J.A. Park, H.A. Kim, E.B. Lee, C. Garlanda, A. Cotena, and Y.W. Song. 2009. Serum levels of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) and pentraxin 3 (PTX3) as markers of infection in febrile patients with systemic lupus erythematosus. Clinical and Experimental Rheumatology 27: 773-778.
34. Means, T.K., E. Latz, F. Hayashi, M.R. Murali, D.T. Golenbock, and A.D. Luster. 2005. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. The Journal of Clinical Investigation 115: 407-417.
35. Papadimitraki, E.D., C. Choulaki, E. Koutala, G. Bertsias, C. Tsatsanis, I. Gergianaki, et al. 2006. Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis and Rheumatism 54: 3601-3611.